Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

NewsGuard 100/100 Score

Schering-Plough Corporation (NYSE: SGP) today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support successful implementation of the projects in ten villages surrounding Bangalore and Pune, India.

"Our company has a commitment to reducing the prevalence of rabies in vulnerable places around the world, and these new initiatives in India demonstrate continuing support of eradication efforts," said Schering-Plough Chairman and CEO Fred Hassan. "As with the Afya Serengeti project that Schering-Plough supports in Africa, educating people about rabies and how to prevent it is the most effective weapon against the disease."

Using the "Adopt a Village" concept, education about rabies prevention and treatment will be aimed at the entire community and adapted for everyone from small children to adults and village leaders. With guidance from the nonprofit Global Alliance for Rabies Control, the programs will involve medical and veterinary professors, experts in the field of rabies along with medical students from area universities. Special accommodations will be made to educate people in their own dialects, with sensitivity to their customs.

"Our goal is to provide a sustainable solution for communities in developing countries to prevent rabies that takes into account how people interact with community dogs and other animals in their environment," said Deborah J. Briggs Ph.D., executive director, Global Alliance for Rabies Control. "Rabies remains a neglected disease of the poor and disenfranchised, and we believe projects such as these being developed in India will serve as models that can be replicated in other vulnerable areas. The grim truth is that every day more than 150 people die of rabies. More than 100 of them are children and every one of the deaths should have been prevented."

Separate but similar projects will be implemented in two geographic areas of India. The Global Alliance for Rabies Control will supervise projects in four selected villages outside the city of Bangalore: Ramohally, Hulluvenahally, Chandrappa circle and Prasanachari palya. The Alliance will partner with a number of India-based groups to ensure maximum impact. Partners from India include the Rabies in Asia Foundation; the National Institute of Mental Health and Neurosciences (NIMHANS); Kempegowda Institute of Medical Sciences (KIMS) and the Veterinary College, Bangalore. The Alliance will also develop educational materials for teaching children worldwide about rabies prevention.

The Bombay Veterinary College, Mumbai, will take the lead role for projects in six major villages in Pune district, namely Narayangaon, Khodad, Arvi Pimpalgaon, Yedgaon, Alephata and Vadgaon Anand. The college will be supported by K.N.P. College of Veterinary Science, Shirval, and Karuna Animal Health Foundation, Narayangaon. Intervet India, the Intervet/Schering-Plough Animal Health business located in the Pune region, will be contributing technical support for the project as an extension of its current rabies prevention efforts.

Rural Indian villages are especially vulnerable to rabies, according to the World Health Organization (WHO). India reports the highest incidence of human rabies accounting for an estimated 20,000 of the 55,000 deaths reported worldwide each year. Three-quarters of the deaths in India occur in rural areas with the highest rates among the poor, particularly children under the age of 15.

The new programs in India will start with surveys to learn how well rabies prevention is understood in the selected villages and to assess the status of rabies among the villages' dog and other animal populations. Researchers will also track the numbers of reported cases and human and animal deaths due to the disease. The next phase of the program will involve massive campaigns of public education, focusing on effective rabies prevention practices for humans and animals as well as appropriate treatment after exposure to the disease.

Education is urgently needed because WHO research shows most deaths occur when people bitten by, or exposed to, a rabid animal do not seek or receive appropriate treatment. In most countries where canine rabies is prevalent, victims of dog bites lack understanding of the importance of seeking appropriate medical treatment from a qualified health facility. Proper wound cleansing and immunizations, done as soon as possible after contact with a suspect animal, can prevent the onset of rabies in virtually 100 percent of exposures, the WHO has found. If left untreated, the fatality rate after rabies infection is 100 percent.

The education campaigns will draw attention to the importance of vaccinating community dogs. Improving community understanding of the life-saving value of administering canine vaccines is crucial; the WHO has determined that the most cost-effective strategy for preventing rabies in people is to eliminate rabies in dogs through animal vaccinations. This will especially benefit children, who typically have closer contact with dogs than adults and are less inclined to report injuries sustained from playing or other interaction with the animals.

The final phase of the Indian projects will involve a comprehensive evaluation of whether the education and vaccination efforts produced measurable improvements in the incidence of rabies in people, dogs and other animals.

Source:

Schering-Plough Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nigeria first to rollout new Men5CV vaccine against meningitis